论文部分内容阅读
目的:评价瑞替普酶和低分子肝素与尿激酶用于治疗急性ST段升高心肌梗死(STEMI)患者的临床疗效和安全性。方法:选取2011年3月-2012年12月间诊治的年龄≤75岁的STEMI患者80例,将其随机分为瑞替普酶组和尿激酶组各40例,各组分别给予瑞替普酶和低分子肝素钠与尿激酶溶栓治疗,比较两组患者溶栓治疗后2,4 h血管再通率、病死率及不良反应的发生情况。结果:瑞替普酶组溶栓治疗后2,4 h血管再通率高于尿激酶组(P<0.05);病死率、不良反应及心血管事件发生率低于尿激酶组(P<0.05)。结论:瑞替普酶和低分子肝素溶栓用于治疗急性心肌梗死患者效果优于尿激酶。
Objective: To evaluate the clinical efficacy and safety of reteplase, low molecular weight heparin and urokinase in the treatment of acute ST-segment elevation myocardial infarction (STEMI). Methods: Eighty STEMI patients aged ≤75 years who were diagnosed and treated from March 2011 to December 2012 were randomly divided into reteplase group and urokinase group, 40 cases in each group were given reteplase Enzyme and low molecular weight heparin and urokinase thrombolytic therapy were used to compare the rates of recanalization, mortality and adverse reactions at 2, 4 h after thrombolysis in both groups. Results: The rate of revascularization at 2 and 4 h after reteplase treatment was higher than that of urokinase (P <0.05). The mortality, adverse reactions and the incidence of cardiovascular events were lower than those of urokinase group (P <0.05) ). Conclusion: The effect of reteplase and low molecular weight heparin thrombolytic therapy in the treatment of acute myocardial infarction patients is better than that of urokinase.